Hikma and Richter enter into an agreement to supply and commercialise cariprazine, an antipsychotic treatment for patients suffering from schizophrenia, in 14 MENA markets.
Hikma Pharmaceuticals and Gedeon Richter have announced an exclusive licensing agreement to commercialize cariprazine, an antipsychotic treatment for patients suffering from schizophrenia. The partnership targets certain Middle East and North African (MENA) markets.
Headquartered in the UK, Hikma said that under the terms of the agreement “Richter will be responsible for product supply...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
